What is Cerebrolysin?
Cerebrolysin is a multimodal neuropeptide preparation studied in stroke, aphasia and neurorehabilitation research. This page summarises the evidence base, including animal-only and in vitro work.
Cerebrolysin is a multimodal neuropeptide preparation derived from porcine brain tissue, used in research as an adjunct to reperfusion, rehabilitation and neuroprotection protocols [1][9]. It is not a single molecule: the evidence block does not give a sequence, formula or molecular weight, and none should be assumed. The preparation is studied chiefly in ischaemic stroke and post-stroke neurological deficit models, where the work centres on neurotrophic and neuroplasticity signalling and on preservation of the blood-brain barrier and cerebral endothelial integrity [1][4].
Identifiers, sequence data and pharmacokinetic parameters are not supplied in the evidence block for this compound. Where a study reports a population, that population is named below; where a finding comes from cells or animals, that is stated plainly.
Research Studies
Cerebrolysin and reperfusion injury after extended-window endovascular thrombectomy
An ongoing multicentre randomised clinical trial is evaluating whether Cerebrolysin, given after successful extended-window endovascular thrombectomy, reduces brain tissue injury and supports recovery in patients with acute ischaemic stroke caused by large-artery occlusion [1]. The trial addresses a specific gap: thrombectomy can benefit selected patients treated 6 to 24 hours after onset, but some remain disabled even when the blocked artery is reopened, and ongoing injury to brain tissue, small vessels and the blood-brain barrier is thought to contribute to that incomplete recovery [1].
Cerebrolysin and basilar artery occlusion after mechanical thrombectomy
A case report described a 67-year-old woman with multiple vascular risk factors who presented with acute basilar artery occlusion and was treated with intravenous thrombolysis followed by successful mechanical thrombectomy (TICI grade 3), with adjunctive Cerebrolysin administered subsequently [2]. Rapid neurological improvement was observed within 24 hours, with NIHSS falling from 7 to 2, followed by complete neurological recovery (NIHSS 0) [2]. This is a single case; it does not establish efficacy.
Cerebrolysin and post-stroke Wernicke's aphasia with speech-language therapy
A case report described a 38-year-old female lawyer who developed acute Wernicke's aphasia and right-sided hemiparesis after ischaemic stroke and, despite timely thrombolysis and mechanical thrombectomy, had significant neurological deficits [3]. Early multidisciplinary rehabilitation combined with a 10-day course of Cerebrolysin was reported [3]. Post-stroke aphasia affects approximately one-third of stroke survivors and impairs communication, social participation and quality of life; speech-language therapy remains the standard of care, and agents such as Cerebrolysin are studied as potential enhancers of recovery through neuroprotection and neuroplasticity [3].
Cerebrolysin and cerebral endothelial permeability in vitro
In an in vitro endothelial permeability assay, exosomes released by Cerebrolysin-treated cerebral endothelial cells (Cerebro-Exos) were tested for their effect on dysfunctional cerebral endothelial cells [4]. Stoichiometric analysis showed marked differences in cargo profiles between Cerebro-Exos and exosomes from untreated cells (Naïve-Exos), with Cerebro-Exos highly enriched in metabolic and tight-junction-related proteins [4]. Cerebro-Exos had a superior effect to Naïve-Exos on restoring endothelial cell integrity impaired by fibrin and tissue plasminogen activator [4]. This is cell-culture work, not a clinical finding.
Cerebrolysin and nonfluent aphasia recovery with speech therapy
A conference abstract reports a meta-analysis of the effect of Cerebrolysin combined with speech therapy on nonfluent aphasia recovery after ischaemic stroke [6]. The evidence block supplies the abstract title only; effect sizes, patient numbers and confidence intervals are not available here and are not reproduced.
Cerebrolysin and virtual reality neurorehabilitation in acute stroke
A conference abstract reports on virtual reality neurorehabilitation in acute stroke patients and the add-on effect of Cerebrolysin [7]. As with the aphasia meta-analysis, only the abstract title is available in the evidence block; no outcome data are given and none are stated here.
Cerebrolysin and 12-month functional outcomes after endovascular thrombectomy
A conference abstract reports 12-month functional outcomes in a propensity-matched cohort of stroke patients who received Cerebrolysin after endovascular thrombectomy [8]. The evidence block provides the abstract title only; the matched cohort size, outcome measure and effect estimate are not available here.
Cerebrolysin and very early short-course use after tenecteplase and thrombectomy
A case report described an 88-year-old woman treated with a very early short course of Cerebrolysin after tenecteplase and mechanical thrombectomy [9]. The report notes that despite high recanalisation rates with mechanical thrombectomy, large-vessel occlusion stroke results in death or dependency in over half of patients, and that Cerebrolysin may attenuate ischaemia-reperfusion injury and support early neurorehabilitation [9]. This is a single case.
Retracted and withdrawn Cerebrolysin studies
Several Cerebrolysin papers have been retracted, and the retraction notices are part of the evidence block. A retraction note covers a study of Cerebrolysin and exacerbation of neuropathic pain, blood-spinal cord barrier breakdown and cord pathology following chronic intoxication with engineered Ag, Cu or Al nanoparticles (50-60 nm) [5]. Further retraction notices cover work on the neurogenic effects of CNTF-derived peptides and Cerebrolysin in AβPP transgenic mice [10], timed release of Cerebrolysin using drug-loaded titanate nanospheres in a Parkinson's disease model [11], and neurotrophic effects of Cerebrolysin in the Mecp2308/Y transgenic model of Rett syndrome [12]. These notices are recorded here because the underlying findings should not be relied on.
Comparison of study types in the Cerebrolysin evidence base
| Study type | Population or model | What the evidence block reports |
|---|---|---|
| Randomised clinical trial (ongoing) | Acute ischaemic stroke, large-artery occlusion, extended-window thrombectomy | Evaluates whether Cerebrolysin after successful thrombectomy reduces brain tissue injury and supports recovery [1] |
| Case report | 67-year-old woman, acute basilar artery occlusion | NIHSS 7 to 2 within 24 hours, then NIHSS 0 [2] |
| Case report | 38-year-old woman, post-stroke Wernicke's aphasia | 10-day Cerebrolysin course alongside multidisciplinary rehabilitation [3] |
| In vitro | Cerebral endothelial cells, permeability assay | Cerebro-Exos enriched in metabolic and tight-junction proteins; superior restoration of integrity impaired by fibrin and tPA [4] |
| Conference abstract | Nonfluent aphasia after ischaemic stroke | Meta-analysis of Cerebrolysin plus speech therapy; no outcome data in evidence block [6] |
| Conference abstract | Acute stroke, virtual reality neurorehabilitation | Add-on effect of Cerebrolysin; no outcome data in evidence block [7] |
| Conference abstract | Propensity-matched cohort after endovascular thrombectomy | 12-month functional outcomes; no outcome data in evidence block [8] |
| Case report | 88-year-old woman, tenecteplase and thrombectomy | Very early short-course Cerebrolysin [9] |
| Retraction notices | Nanoparticle intoxication model; AβPP transgenic mice; titanate nanospheres in Parkinson's model; Mecp2308/Y Rett model | Underlying findings retracted [5][10][11][12] |
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance, and nothing on this page is medical advice. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy — https://clinicaltrials.gov/study/NCT06339411
- [2] Adjunctive Cerebrolysin therapy following mechanical thrombectomy for acute basilar artery occlusion: a case report — https://europepmc.org/article/PMC/PMC13474398
- [3] Cerebrolysin as an adjunct to speech-language therapy in post-stroke Wernicke's aphasia: a case report — https://europepmc.org/article/PMC/PMC13474394
- [4] Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability — https://europepmc.org/article/PMC/PMC13205112
- [5] Retraction Note: Cerebrolysin Attenuates Exacerbation of Neuropathic Pain, Blood-Spinal Cord Barrier Breakdown and Cord Pathology Following Chronic Intoxication of Engineered Ag, Cu or Al (50-60 nm) Nanoparticles — https://europepmc.org/article/PMC/PMC13179879
- [6] ABSTRACT NUMBER: ESOC2026A102 META-ANALYSIS: THE EFFECT OF CEREBROLYSIN COMBINED WITH SPEECH THERAPY ON NONFLUENT APHASIA RECOVERY AFTER ISCHEMIC STROKE — https://europepmc.org/article/PMC/PMC13146077
- [7] ABSTRACT NUMBER: ESOC2026A822 VIRTUAL REALITY NEUROREHABILITATION IN ACUTE STROKE PATIENTS AND THE ADD-ON EFFECT OF CEREBROLYSIN — https://europepmc.org/article/PMC/PMC13145624
- [8] ABSTRACT NUMBER: ESOC2026A562 CEREBROLYSIN AFTER ENDOVASCULAR THROMBECTOMY IN STROKE: 12-MONTH FUNCTIONAL OUTCOMES IN A PROPENSITY-MATCHED COHORT — https://europepmc.org/article/PMC/PMC13146562
- [9] Very Early Short-Course Cerebrolysin After Tenecteplase and Mechanical Thrombectomy: A Case Report — https://pubmed.ncbi.nlm.nih.gov/42666484/
- [10] Retraction: Regional Comparison of the Neurogenic Effects of CNTF-Derived Peptides and Cerebrolysin in AβPP Transgenic Mice — https://pubmed.ncbi.nlm.nih.gov/42015030/
- [11] Retraction Note to: Timed Release of Cerebrolysin Using Drug-Loaded Titanate Nanospheres Reduces Brain Pathology and Improves Behavioral Functions in Parkinson's Disease — https://pubmed.ncbi.nlm.nih.gov/41920231/
- [12] Retraction Note: Neurotrophic effects of Cerebrolysin in the Mecp2308/Y transgenic model of Rett syndrome — https://pubmed.ncbi.nlm.nih.gov/41874695/